Skeletal dysplasias of the parathyroid hormone signaling cascade: radiological manifestations and molecular mechanisms.
This study categorizes skeletal dysplasias based on defects in the parathyroid hormone signaling cascade, offering insights into their molecular mechanisms and radiological features.
Where it sits
this study against the rest of the abaloparatide (tymlos) corpusSummary and findings
The paper discusses skeletal dysplasias related to the parathyroid hormone signaling cascade, focusing on genetic defects affecting PTH and PTHrP signaling. It highlights the radiological and molecular manifestations of these disorders, including osteolysis, osteosclerosis, and growth plate abnormalities. The study categorizes these dysplasias based on their pathophysiologic mechanisms.
Abstract
Recent classification of skeletal dysplasias has reclassified disorders according to their underlying pathophysiologic mechanisms. The latest nosology of skeletal dysplasias introduced a new pathogenic category termed "skeletal disorders of the parathyroid hormone (PTH) signaling cascade." The group encompasses genetic defects associated with abnormal signaling of PTH, PTH-related protein (PTHrP) encoded by the PTHLH (PTH-like hormone) gene, and their common receptor termed parathyroid hormone 1 receptor (PTH1R). PTH1R is a guanine nucleotide-binding protein (G protein)-coupled receptor; and thus, defects of the a-subunit of stimulatory G protein (G<sub>s</sub>α) and its downstream effectors cause disorders that overlap with those of the PTH signaling cascade. PTH and PTHrP have both catabolic and anabolic effects on bone metabolism, while PTHrP inhibits maturation of chondrocytes. Therefore, increased signaling of the cascade includes osteolysis that may be accompanied by focal osteosclerosis and/or delayed ossification of the growth plate or metaphyseal dysplasia. Partial loss of signaling can present as type E brachydactyly due to premature maturation of the growth plate of short tubular bones, typically exemplified by pseudohypoparathyroidism. Total loss of signaling leads to osteosclerosis and significantly accelerated bone maturation seen in a lethal sclerosing bone dysplasia termed Blomstrand dysplasia.
Background
Skeletal dysplasias are a diverse group of disorders affecting bone growth and development, often classified by their genetic and molecular underpinnings. This study focuses on a newly defined category of skeletal dysplasias linked to abnormalities in the parathyroid hormone signaling cascade. Understanding these mechanisms is crucial for accurate diagnosis and potential therapeutic targeting.
Methods
Not reported in abstract.
Results
The study identifies genetic defects in the PTH signaling pathway, affecting PTH, PTHrP, and their receptor PTH1R. These defects result in a spectrum of skeletal manifestations, including osteolysis, focal osteosclerosis, and growth plate dysplasia. Specific conditions such as type E brachydactyly and Blomstrand dysplasia are associated with partial and total loss of signaling, respectively.
Interpretation
The findings provide a molecular basis for classifying certain skeletal dysplasias, which may aid in differential diagnosis and understanding of these conditions. However, the clinical significance of these findings depends on further research to explore potential therapeutic interventions. The study highlights the complexity of PTH signaling in bone metabolism and its implications for skeletal health.
Key findings
- New pathogenic category termed 'skeletal disorders of the parathyroid hormone signaling cascade'.
- PTH1R is a G protein-coupled receptor involved in these disorders.
- Increased signaling can cause osteolysis and delayed ossification.
- Partial loss of signaling presents as type E brachydactyly.
- Total loss of signaling leads to Blomstrand dysplasia.
Limitations
- Not reported in abstract.